Asgard Therapeutics, a Swedish biotech company focused on in vivo direct cell reprogramming for cancer immunotherapy, announced on Tuesday the appointment of Prof Dr Wolfram Brugger as chief medical officer.

The company said that Prof Dr Brugger, who has been involved in more than 130 Phase I-III clinical oncology trials with numerous modalities across a wide variety of cancer types, including solid tumours, will strengthen its leadership as it prepares to transition to a clinical-stage biotech.

Wolfram joins Asgard from Autolus Therapeutics, where he led the global clinical development programme of AUTO1 (AUCATZYL(R) / obe-cel), an autologous CD19 CAR T therapy, in haematological and autoimmune indications. AUTO1 received FDA approval in 2024 for relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) and conditional approval was granted by the EMA and MHRA in 2025. Prior to this he was at MorphoSys where he headed the global clinical development programme for the monoclonal antibody tafasitamab across various blood cancer indications. At AstraZeneca, he was global medical lead for Phase I/early Phase II trials for several oncology assets in numerous cancer types, including testing them in combination with checkpoint inhibitors.

Asgard is currently focused on advancing IND-enabling studies and CMC activities to support clinical development of its lead asset AT-108.